---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-235598"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:37:39.651380+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tempest inks Roche atezolizumab supply deal for Phase 3 liver cancer trial; extends rights plan

## Summary
- Master clinical supply agreement with Roche for free atezolizumab in planned Phase 3 trial of amezalpat (TPST-1120) in first-line unresectable/metastatic HCC.
- Phase 3 study: TPST-1120 + atezolizumab + bevacizumab vs placebo + atezolizumab + bevacizumab; Tempest retains all data from the trial.
- Board extended rights plan to expire after 2025 annual meeting or Oct 2026 if stockholders approve, citing stock undervaluation after positive survival data and FDA alignment.
- Rights plan triggers at 10% beneficial ownership (15% for passive institutions), with grandfathering for existing holders above threshold.

## SEC filing metadata
- accession: 0001193125-24-235598
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312524235598/0001193125-24-235598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312524235598/d877681d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-235598
- JSON: https://secwatch.observer/filing/0001193125-24-235598.json
- Plain text: https://secwatch.observer/filing/0001193125-24-235598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.